Skip to search formSkip to main contentSkip to account menu

CA602 antigen

Known as: CA602 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antigens, Tumor-Associated, Carbohydrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
[CA546, CA602].
Review
1999
Review
1999
[CA546, CA602].
1998
1998
Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT).
1994
1994
[Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Serum samples from patients with benign or malignant diseases were measured for the newly developed tumor markers CA54/61 and… 
1993
1993
[Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor…
Galactosyltransferase Associated with Tumor (GAT) was clinically studied in cases of ovarian cancer. When two cut-off levels of… 
Review
1992
Review
1992
[Tumor markers of ovarian cancer].
Many of the recently developed tumor markers are carbohydrate antigens, and are clinically useful for the diagnosis of ovarian… 
1991
1991
A New CA125‐like Antigen (CA602) Recognized by Two Monoclonal Antibodies against a Newly Established Ovarian Clear Cell Carcinoma Cell Line (RMG‐II)
A cell line designated RMG‐II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal… 
1990
1990
[Clinical value of a new serum tumor marker CA602 in ovarian cancers].
We investigated the usefulness of CA602, a newly developed serum tumor marker, for ovarian cancer. When the cut-off value was set… 
1990
1990
260 Clinical usefulness to assay serum levels of CA54/61 and CA602 in ovarian cancer.
1990
1990
146 Clinical usefulness of three new ovarian tumor markers, CA54/61, CA602 and caGT.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)